Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk
- To determine the effect of cyproheptadine hydrochloride in the prevention of cancer- or
treatment-related weight loss (defined as ≥ 5% reduction in weight from baseline
measurement) in children who are initiating a course of moderately or highly emetic
- To investigate the effect of cyproheptadine HCl on the change in weight for age scores
after 8 weeks of study drug administration in comparison to placebo.
- Investigate the relationship between the secondary outcome variables (prealbumin,
triceps skin fold, mid-upper arm circumference, and weight loss)from baseline to end of
treatment in each group (treatment and placebo) separately.
OUTLINE: This is a multicenter study. Patients are stratified according to enrolling center
and steroid use with cancer treatment (yes vs no). Study agent can start anytime up to and
including day 28 after the first dose of chemotherapy.
- Arm I: Patients receive oral cyproheptadine hydrochloride twice daily for 8 weeks.
- Arm II: Patients receive an oral placebo twice daily for 8 weeks.
Patients undergo weight and height measurements at baseline and at each follow-up visit in
weeks 4 and 8 to evaluate the effect of cyproheptadine hydrochloride and duration of
response. Patients or parents complete medicine logs at each follow-up visit in weeks 4 and
8 to evaluate drug compliance and tolerance. Patients also undergo measures of nutrition;
and measures of body composition, lean body mass, and fat percentage using standardized
equipment and procedures for measuring triceps skin fold and mid-arm muscle circumference at
baseline and at the end of the study.
Patients undergo blood sample collection at baseline and at the end of the study for
biomarker studies. Samples are analyzed for pre-albumin levels.
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Supportive Care
Efficacy of cyproheptadine HCl in the prevention of cancer/treatment-related weight loss, defined as weight loss ≥ 5% at the 4 or 8- week assessment when compared to baseline
Jeffrey P. Krischer, PhD
University of South Florida
United States: Data and Safety Monitoring Board
|Children's Hospital of Southwest Florida||Fort Myers, Florida 33908|
|Children's Hospital of the King's Daughters||Norfolk, Virginia 23507|
|Nemours Children's Clinic - Orlando||Orlando, Florida 32806|
|Cincinnati Children's Hospital Medical Center||Cincinnati, Ohio 45229-3039|
|Connecticut Children's Medical Center||Hartford, Connecticut 06106|
|Kapiolani Medical Center for Women and Children||Honolulu, Hawaii 96826|
|CHRISTUS Santa Rosa Children's Hospital||San Antonio, Texas 78207|
|Arnold Palmer Hospital for Children||Orlando, Florida 32806|
|Miller Children's Hospital||Long Beach, California 90806|
|Nemours Children's Clinic - Jacksonville||Jacksonville, Florida 32207-8426|